LhARA Steering Group meeting #4

24^th September 2020 10:00 GMT

Connection details

ZOOM meeting: ​https://cern.zoom.us/j/95417789956?pwd=Nk9DZmwxc3R0SjdScjlVeEFrRlRwdz09

Agenda

1. Notes of last meeting and actions arising:
   • KL: Set up series of meetings with leads at partner organisations to discuss preparation of R&D programme.
     • Superceded.
   • KL/CB: Consider meeting between Imperial (and other) ion-accelerator experts with the relevant experts in CLF.
     • Ongoing.
   • KL/KK: to collaborate on the development for a proposal for such a meeting on the timescale of November 2020.
     • Ongoing.
   • KL: Ensure one representative per group at the next LhARA SG meeting.
     • Stands.
   • KL: Raise NIHR engagement with K.Gleeson.
     • Done.
   • KL: Seek PPI representative for SG.
     • Done. Welcome G. Jones and H. Hall.
   • KK, JPar, CW, KL: Make relevant contact with local PPI groups as described in item 4.
   • KL&JPar: Write to CTRAD w/s 4 chair (KK) to ask how we might work together to raise awarenents of our programme among the patient and clinician communitites.
     • Done. Letter written and sent, see under clinician engagement below. Revised action needs to be agreed.
   • KK, JPar, CW, KL, SG: Make relevant contact with local clinician groups as described in item 4.
     • Ongoing.
   • KL: Write to J.Clarke to ask for support to reach out to relevant industry.
     • Stands.
   • PA: Make contact with MTC to see how to make contact with relevant industry. PA/KL will cooperate in drafting a letter.
   • KL: Review proposed w/p structure and skills matrix taking into account comments under item 4.
     • Stands.&&
   • KL/RMcL: Liaise to generate small group to coordinate development of instrumentation aspects of the programme.
     • Done. Meeting organised between A.Price and R.McLauchlan a success.

2. Update on progress: KL
   

3. ​EPSRC Transformative Healthcare Technologies call: KL/All
   • Dealing with feedback from our 2019 submission:
     "Engagement with patients, clinicians and industry could have been strengthened"
     • Patient engagement:
       • Actions taken to date;
       • Need for local action by partner;
       • Subsequent coordination
     • Clinician engagement:
       • Actions taken to date;
       • Need for local action by partner;
       • Subsequent coordination
     • Industrial engagement:
       • Actions taken to date;
       • Discussion of next steps
   • Slides to initiate discussion of:
     • Scope;
     • Initial discussion of work packages;
     • Stakeholders from whom we should be seeking support;
   • Next steps discussion

4. Follow-up Discussion of dedicated advanced diagnostics and instrumentation for the in vitro and in vivo end stations: KL/all

5. DONMs
   
   • TBD

6. AoB
   

---